Medical - Diagnostics & Research
Compare Stocks
5 / 10Stock Comparison
SHC vs STRL vs ICLR vs CRL vs MEDP
Revenue, margins, valuation, and 5-year total return — side by side.
Engineering & Construction
Medical - Diagnostics & Research
Medical - Diagnostics & Research
Medical - Diagnostics & Research
SHC vs STRL vs ICLR vs CRL vs MEDP — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Diagnostics & Research | Engineering & Construction | Medical - Diagnostics & Research | Medical - Diagnostics & Research | Medical - Diagnostics & Research |
| Market Cap | $4.47B | $24.89B | $9.54B | $8.98B | $12.24B |
| Revenue (TTM) | $1.19B | $2.88B | $8.10B | $4.03B | $2.68B |
| Net Income (TTM) | $118M | $347M | $599M | $-185M | $460M |
| Gross Margin | 55.3% | 22.8% | 26.9% | 24.9% | 29.1% |
| Operating Margin | 34.9% | 17.0% | 12.2% | 11.8% | 21.0% |
| Forward P/E | 16.3x | 59.1x | 10.5x | 16.4x | 25.2x |
| Total Debt | $2.27B | $350M | $3.60B | $3.07B | $250M |
| Cash & Equiv. | $346M | $391M | $539M | $214M | $497M |
SHC vs STRL vs ICLR vs CRL vs MEDP — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Nov 20 | May 26 | Return |
|---|---|---|---|
| Sotera Health Compa… (SHC) | 100 | 57.9 | -42.1% |
| Sterling Infrastruc… (STRL) | 100 | 5074.5 | +4974.5% |
| ICON Public Limited… (ICLR) | 100 | 64.1 | -35.9% |
| Charles River Labor… (CRL) | 100 | 77.6 | -22.4% |
| Medpace Holdings, I… (MEDP) | 100 | 334.0 | +234.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SHC vs STRL vs ICLR vs CRL vs MEDP
Each card shows where this stock fits in a portfolio — not just who wins on paper.
SHC is the clearest fit if your priority is income & stability and sleep-well-at-night.
- Dividend streak 2 yrs, beta 1.32
- Lower volatility, beta 1.32, current ratio 2.46x
- Beta 1.32, current ratio 2.46x
STRL is the #2 pick in this set and the best alternative if long-term compounding is your priority.
- 176.9% 10Y total return vs MEDP's 14.4%
- +351.7% vs ICLR's -10.0%
ICLR ranks third and is worth considering specifically for value.
- Lower P/E (10.5x vs 16.4x)
Among these 5 stocks, CRL doesn't own a clear edge in any measured category.
MEDP carries the broadest edge in this set and is the clearest fit for growth exposure and valuation efficiency.
- Rev growth 20.0%, EPS growth 21.0%, 3Y rev CAGR 20.1%
- PEG 0.79 vs ICLR's 1.50
- 20.0% revenue growth vs CRL's -0.9%
- 17.2% margin vs CRL's -4.6%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 20.0% revenue growth vs CRL's -0.9% | |
| Value | Lower P/E (10.5x vs 16.4x) | |
| Quality / Margins | 17.2% margin vs CRL's -4.6% | |
| Stability / Safety | Beta 1.26 vs STRL's 2.54 | |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | +351.7% vs ICLR's -10.0% | |
| Efficiency (ROA) | 24.8% ROA vs CRL's -2.5%, ROIC 154.9% vs 6.3% |
SHC vs STRL vs ICLR vs CRL vs MEDP — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
SHC vs STRL vs ICLR vs CRL vs MEDP — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
SHC leads in 2 of 6 categories
ICLR leads 1 • MEDP leads 1 • STRL leads 1 • CRL leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
SHC leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ICLR is the larger business by revenue, generating $8.1B annually — 6.8x SHC's $1.2B. MEDP is the more profitable business, keeping 17.2% of every revenue dollar as net income compared to CRL's -4.6%. On growth, STRL holds the edge at +91.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $1.2B | $2.9B | $8.1B | $4.0B | $2.7B |
| EBITDAEarnings before interest/tax | $517M | $575M | $1.4B | $757M | $577M |
| Net IncomeAfter-tax profit | $118M | $347M | $599M | -$185M | $460M |
| Free Cash FlowCash after capex | $112M | $440M | $996M | $391M | $745M |
| Gross MarginGross profit ÷ Revenue | +55.3% | +22.8% | +26.9% | +24.9% | +29.1% |
| Operating MarginEBIT ÷ Revenue | +34.9% | +17.0% | +12.2% | +11.8% | +21.0% |
| Net MarginNet income ÷ Revenue | +9.9% | +12.0% | +7.4% | -4.6% | +17.2% |
| FCF MarginFCF ÷ Revenue | +9.4% | +15.3% | +12.3% | +9.7% | +27.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +10.0% | +91.6% | +0.6% | +1.2% | +26.5% |
| EPS Growth (YoY)Latest quarter vs prior year | +2.9% | +141.4% | -98.7% | -160.0% | +16.6% |
Valuation Metrics
ICLR leads this category, winning 5 of 7 comparable metrics.
Valuation Metrics
At 13.1x trailing earnings, ICLR trades at a 85% valuation discount to STRL's 86.5x P/E. Adjusting for growth (PEG ratio), MEDP offers better value at 0.88x vs STRL's 1.95x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $4.5B | $24.9B | $9.5B | $9.0B | $12.2B |
| Enterprise ValueMkt cap + debt − cash | $6.4B | $24.9B | $12.6B | $11.8B | $12.0B |
| Trailing P/EPrice ÷ TTM EPS | 58.04x | 86.50x | 13.12x | -62.52x | 28.06x |
| Forward P/EPrice ÷ next-FY EPS est. | 16.26x | 59.12x | 10.53x | 16.42x | 25.24x |
| PEG RatioP/E ÷ EPS growth rate | — | 1.95x | 1.87x | — | 0.88x |
| EV / EBITDAEnterprise value multiple | 21.09x | 50.58x | 7.95x | 12.98x | 21.31x |
| Price / SalesMarket cap ÷ Revenue | 3.84x | 10.00x | 1.15x | 2.24x | 4.84x |
| Price / BookPrice ÷ Book value/share | 7.41x | 22.70x | 1.09x | 2.81x | 27.57x |
| Price / FCFMarket cap ÷ FCF | 29.95x | 68.64x | 8.53x | 17.31x | 17.96x |
Profitability & Efficiency
MEDP leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
MEDP delivers a 120.9% return on equity — every $100 of shareholder capital generates $121 in annual profit, vs $-6 for CRL. STRL carries lower financial leverage with a 0.32x debt-to-equity ratio, signaling a more conservative balance sheet compared to SHC's 3.75x. On the Piotroski fundamental quality scale (0–9), ICLR scores 7/9 vs CRL's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +20.6% | +32.3% | +6.3% | -5.7% | +120.9% |
| ROA (TTM)Return on assets | +3.7% | +13.7% | +3.6% | -2.5% | +24.8% |
| ROICReturn on invested capital | +11.8% | +38.9% | +6.5% | +6.3% | +154.9% |
| ROCEReturn on capital employed | +13.3% | +28.5% | +7.8% | +8.1% | +65.7% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 6 | 7 | 4 | 6 |
| Debt / EquityFinancial leverage | 3.75x | 0.32x | 0.38x | 0.95x | 0.55x |
| Net DebtTotal debt minus cash | $1.9B | -$41M | $3.1B | $2.9B | -$247M |
| Cash & Equiv.Liquid assets | $346M | $391M | $539M | $214M | $497M |
| Total DebtShort + long-term debt | $2.3B | $350M | $3.6B | $3.1B | $250M |
| Interest CoverageEBIT ÷ Interest expense | 2.38x | 27.17x | 3.96x | 6.38x | — |
Total Returns (Dividends Reinvested)
STRL leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in STRL five years ago would be worth $350,047 today (with dividends reinvested), compared to $5,311 for CRL. Over the past 12 months, STRL leads with a +351.7% total return vs ICLR's -10.0%. The 3-year compound annual growth rate (CAGR) favors STRL at 167.8% vs ICLR's -13.0% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -11.4% | +154.2% | -33.7% | -10.1% | -24.9% |
| 1-Year ReturnPast 12 months | +19.2% | +351.7% | -10.0% | +32.8% | +42.9% |
| 3-Year ReturnCumulative with dividends | +4.6% | +1819.6% | -34.1% | -4.2% | +104.6% |
| 5-Year ReturnCumulative with dividends | -36.3% | +3400.5% | -45.4% | -46.9% | +159.4% |
| 10-Year ReturnCumulative with dividends | -37.6% | +17694.1% | +91.0% | +119.2% | +1442.7% |
| CAGR (3Y)Annualised 3-year return | +1.5% | +167.8% | -13.0% | -1.4% | +27.0% |
Risk & Volatility
Evenly matched — STRL and MEDP each lead in 1 of 2 comparable metrics.
Risk & Volatility
MEDP is the less volatile stock with a 1.26 beta — it tends to amplify market swings less than STRL's 2.54 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. STRL currently trades 91.3% from its 52-week high vs ICLR's 59.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.32x | 2.54x | 1.60x | 1.52x | 1.26x |
| 52-Week HighHighest price in past year | $19.85 | $888.95 | $211.00 | $228.88 | $628.92 |
| 52-Week LowLowest price in past year | $10.80 | $171.38 | $66.57 | $131.30 | $284.48 |
| % of 52W HighCurrent price vs 52-week peak | +78.9% | +91.3% | +59.2% | +79.5% | +68.2% |
| RSI (14)Momentum oscillator 0–100 | 56.5 | 88.3 | 62.1 | 57.2 | 40.6 |
| Avg Volume (50D)Average daily shares traded | 3.1M | 498K | 1.1M | 806K | 371K |
Analyst Outlook
SHC leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: SHC as "Buy", STRL as "Buy", ICLR as "Buy", CRL as "Buy", MEDP as "Hold". Consensus price targets imply 40.4% upside for SHC (target: $22) vs -39.8% for STRL (target: $488).
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | $22.00 | $488.20 | $149.63 | $205.43 | $498.86 |
| # AnalystsCovering analysts | 12 | 9 | 30 | 36 | 19 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | 2 | 1 | — | 1 | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.3% | +5.2% | +4.0% | +7.5% |
SHC leads in 2 of 6 categories (Income & Cash Flow, Analyst Outlook). ICLR leads in 1 (Valuation Metrics). 1 tied.
SHC vs STRL vs ICLR vs CRL vs MEDP: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is SHC or STRL or ICLR or CRL or MEDP a better buy right now?
For growth investors, Medpace Holdings, Inc.
(MEDP) is the stronger pick with 20. 0% revenue growth year-over-year, versus -0. 9% for Charles River Laboratories International, Inc. (CRL). ICON Public Limited Company (ICLR) offers the better valuation at 13. 1x trailing P/E (10. 5x forward), making it the more compelling value choice. Analysts rate Sotera Health Company (SHC) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — SHC or STRL or ICLR or CRL or MEDP?
On trailing P/E, ICON Public Limited Company (ICLR) is the cheapest at 13.
1x versus Sterling Infrastructure, Inc. at 86. 5x. On forward P/E, ICON Public Limited Company is actually cheaper at 10. 5x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Medpace Holdings, Inc. wins at 0. 79x versus ICON Public Limited Company's 1. 50x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — SHC or STRL or ICLR or CRL or MEDP?
Over the past 5 years, Sterling Infrastructure, Inc.
(STRL) delivered a total return of +34. 0%, compared to -46. 9% for Charles River Laboratories International, Inc. (CRL). Over 10 years, the gap is even starker: STRL returned +176. 9% versus SHC's -37. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — SHC or STRL or ICLR or CRL or MEDP?
By beta (market sensitivity over 5 years), Medpace Holdings, Inc.
(MEDP) is the lower-risk stock at 1. 26β versus Sterling Infrastructure, Inc. 's 2. 54β — meaning STRL is approximately 102% more volatile than MEDP relative to the S&P 500. On balance sheet safety, Sterling Infrastructure, Inc. (STRL) carries a lower debt/equity ratio of 32% versus 4% for Sotera Health Company — giving it more financial flexibility in a downturn.
05Which is growing faster — SHC or STRL or ICLR or CRL or MEDP?
By revenue growth (latest reported year), Medpace Holdings, Inc.
(MEDP) is pulling ahead at 20. 0% versus -0. 9% for Charles River Laboratories International, Inc. (CRL). On earnings-per-share growth, the picture is similar: Sotera Health Company grew EPS 68. 8% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, MEDP leads at 20. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — SHC or STRL or ICLR or CRL or MEDP?
Medpace Holdings, Inc.
(MEDP) is the more profitable company, earning 17. 8% net margin versus -3. 6% for Charles River Laboratories International, Inc. — meaning it keeps 17. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SHC leads at 33. 8% versus 12. 6% for CRL. At the gross margin level — before operating expenses — SHC leads at 55. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is SHC or STRL or ICLR or CRL or MEDP more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Medpace Holdings, Inc. (MEDP) is the more undervalued stock at a PEG of 0. 79x versus ICON Public Limited Company's 1. 50x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, ICON Public Limited Company (ICLR) trades at 10. 5x forward P/E versus 59. 1x for Sterling Infrastructure, Inc. — 48. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SHC: 40. 4% to $22. 00.
08Which pays a better dividend — SHC or STRL or ICLR or CRL or MEDP?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is SHC or STRL or ICLR or CRL or MEDP better for a retirement portfolio?
For long-horizon retirement investors, Medpace Holdings, Inc.
(MEDP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26), +1443% 10Y return). Sterling Infrastructure, Inc. (STRL) carries a higher beta of 2. 54 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MEDP: +1443%, STRL: +176. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between SHC and STRL and ICLR and CRL and MEDP?
These companies operate in different sectors (SHC (Healthcare) and STRL (Industrials) and ICLR (Healthcare) and CRL (Healthcare) and MEDP (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: SHC is a small-cap quality compounder stock; STRL is a mid-cap high-growth stock; ICLR is a small-cap deep-value stock; CRL is a small-cap quality compounder stock; MEDP is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.